Mechanism-based treatment in chronic neuropathic pain: The role of antidepressants

Current Pharmaceutical Design

Volumn 11, Issue 23, 2005, Pages 2945-2960

  Coluzzi, Flaminia ^a,b   Mattia, Consalvo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b NONE   (Italy)

Author keywords

Analgesia; Antidepressants; Antinociception; Mechanism of action; Mirtazapine; Neuropathic pain; Newer antidepressants; Venlafaxine

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CAPSAICIN; CARBAMAZEPINE; CLOMIPRAMINE; DESIPRAMINE; GABAPENTIN; IMIPRAMINE; MIRTAZAPINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NALOXONE; NEFAZODONE; NEW DRUG; NORADRENALIN; NORADRENALIN UPTAKE INHIBITOR; NORTRIPTYLINE; OPIATE; OPIATE ANTAGONIST; OXAPROTILINE; PAROXETINE; POTASSIUM CHANNEL STIMULATING AGENT; REBOXETINE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SODIUM CHANNEL BLOCKING AGENT; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE;

ACUTE HEART INFARCTION; ANALGESIC ACTIVITY; CHRONIC PAIN; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONSTIPATION; DIZZINESS; DOSE RESPONSE; DROWSINESS; DRUG CHOICE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SELECTIVITY; DRUG STRUCTURE; HEART ARRHYTHMIA; HUMAN; NEUROPATHIC PAIN; NONHUMAN; ORTHOSTATIC HYPOTENSION; PRIAPISM; PRIORITY JOURNAL; REVIEW; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; URINE RETENTION; VISUAL IMPAIRMENT; WEIGHT GAIN; WITHDRAWAL SYNDROME; XEROSTOMIA;

ANIMALS; ANTIDEPRESSIVE AGENTS; BIOGENIC MONOAMINES; CHRONIC DISEASE; HUMANS; PAIN; PERIPHERAL NERVOUS SYSTEM DISEASES;

EID: 23844432593     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612054864993     Document Type: Review

References (126)

1. Vu TH. Current pharmacologic approaches to treating neuropathic pain. Curr Pain Headache Rep 2004; 8: 15-8.
2. Paoli F, Darcourt G, Corsa P. Note preliminaire sur l'action de l'imipramine dans les etats douloureux. Rev Neurol 1960; 2: 503-4.
3. Lynch ME. Antidepressants as analgesics: a review of randomized controlled trials. J Psychiatry Neurosci 2001, 26 (1): 30-6.
4. Fishbain DA, Curtler R, Rosomoff HL, Rosomoff RS. Chronic pain-associated depression: antecedent or consequence of chronic pain? A review. Clin J Pain 1997; 13 (2): 116-37.
5. Verma S, Gallagher RM. The psycopharmacologic treatment of depression and anxiety in the context of chronic pain. Curr Pain and Headache Rep 2002; 6: 30-9.
6. Sawynok J. Antidepressants as analgesics: an introduction. J Psychiatry Neurosci 2001; 26 (1): 20.
7. Onghena P, Van Hondenhove B. Antidepressant-induced analgesia in chronic non-malignant pain: a meta-analysis of 39 placebo controlled studies. Pain 1992; 49(2): 205-19.
8. Valverde O, Mico JA, Maldonaldo R, Mellado M, Gilbert-Rahola J. Participation of opioid and monoaminergic mechanisms on the antinociceptive effect induced by tricyclic antidepressants to behavioural pain tests in mice. Prog Neuropsychopharmacol Biol Psychiatry 1994; 18(6):1073-92.
9. Millan MJ. Descending control of pain. Prog Neurobiol 2002; 66: 355-474.
10. Micò JA, Gilbert-Rahola J, Casas J, Rojas O, Serrano MI, Serrano JS. Implication of beta 1- and beta 2- adrenergic receptors in the antinociceptive effect of tricyclic antidepressants. Eur Neuropsycopharmacol 1997; 7: 139-45.
11. Eschalier A, Montastruc JL, Devoize JL, Rigal F, Gaillard-Plaza G, Pechadre JC. Influence of Naloxone and methysergide on the analgesic effect of clomipramine in rats. Eur J Pharmacol 1981; 74: 1-7.
12. Sierralta F, Pinardi G, Miranda HF. Effect of p-chlorophenylalanine and alpha-methyltyrosine on the antinociceptive effect of antidepressant drugs. Pharmacol Toxicol 1995; 77: 276-80.
13. Sanjue H, Jun Z. Sympathetic facilitation of sustained discharges of polymodal nociceptors. Pain 1989; 38: 85-90.
14. Sato J, Perl ER. Adrenergic excitation of cutaneous pain receptors induced by peripheral nerve injury. Science 1991; 251: 1608-11.
15. Rumore MM, Schlichting DA. Clinical efficacy of antihistaminics as analgesics. Pain 1986; 25: 7-22.
16. Hall H, Ögren S-O. Effects of antidepressant drugs on different receptors in the brain. Eur J Pharmacol 1981; 70: 393-407.
17. Schreiber S, Backer MM, Pick CG. The antinociceptive effect of venlafaxine in mice is mediated through opioid and adrenergic mechanisms. Neuroscience Lett 1999; 273: 85-8.
18. Schreiber S, Rigai T, Katz Y, Pick CG. The antinociceptive effect of mirtazapine in mice is mediated through serotoninergic, noradrenergic and opioid mechanism. Brain Res Bull 2002; 58 (6): 601-5.
19. Marchand F, Ardid D, Chapuy E, Alloui A, Jourdan D, Eschalier A. Evidence for an involvement of supraspinal delta- and spinal mu-opioid receptors in the antihyperalgesic effect of chronically administered clomipramine in mononeuropathic rats. J Pharmacol Exp Ther 2003; 307(1): 268-74.
20. Valverde O, Mico JA, Maldonado R, Mellado M, Gibert-Rahola J. Participation of opioid and monoaminergic mechanisms on the antinociceptive effect induced by tricyclic antidepressants in two behavioural pain tests in mice. Prog Neuropsychopharmacol Biol Psychiatry 1994; 18(6): 1073-92.
21. Duman EN, Kesim M, Kadioglu M, Yaris E, Kalyoncu NI, Erciyes N. Possible involvement of opioidergic and serotonergic mechanisms in antinociceptive effect of paroxetine in acute pain. J Pharmacol Sci 2004; 94(2): 161-5.
22. Wesolowska A, Borycz J. Participation of opioid mechanism in the antinociceptive effects induced by oxaprotiline enantiomers in mice. Pol J Pharmacol 1999; 51(4): 367-71.
23. Gray AM, Spencer PS, Sewell RD The involvement of the opioidergic system in the antinociceptive mechanism of action of antidepressant compounds. Br J Pharmacol 1998; 124(4): 669-74.
24. De Felipe MC, De Ceballos ML, Gil C. Chronic antidepressant treatment increases enkephalin levels in nucleus accumbens and striatum of the rat. Eur J Pharmacol 1985; 112:119-22.
25. Reynolds IJ, Miller RJ. Tricyclic antidepressants block N-methyl-D-aspartate receptors: similarities to the action of zinc. Brit J Pharmacol 1988; 95: 95-102.
26. 2+ levels in neuronal culture. Eur J Pharmacol 1992; 219: 53-7.
27. Choi JJ, Huang GJ, Shafik E, McArdle JJ. Imipramine's selective suppression of an L-type calcium channel in neurons of murine dorsal root ganglia involves G proteins. Pharmacol Exp Ther 1992; 263: 49-53.
28. Chaplan SR, Pogrel JW, Yaksh TL. Role of voltage-dependant calcium channel subtypes in experimental tactile allodynia. Pharmacol Exp Ther 1994; 269: 1117-23.
29. Galeotti N, Ghelardini C, Bartolini A. Involvement of potassium channels in amitriptyline and clomipramine analgesia. Neuropharmacology 2001; 40(1): 75-84.
30. Ogata N, Yoshii M, Narahashi T. Psycotropic drugs block voltage-gated ion channels in neuroblastoma cells. Brain Res 1989; 476: 140-4.
31. Giardina EGV, Bigger JT, Glassman AH, Perel JM, Kantor SJ. The electrocardiographic and antiarrhythmic effects of imipramine hydrocloride at therapeutic plasma concentrations. Circulation 1979; 60: 1045-52.
32. Ballal PM, Mandhane SN, Chopde CT, Muthal AV. GABAergic agents modify imipramine analgesia. Indian J Physiol Pharmacol 1996; 40(1): 95-7.
33. Zarrindast M, Valizadeh S, Sahebgharani M. GABA(B) receptor mechanism and imipramine-induced antinociception in ligated and non-ligated mice. Eur J Pharmacol 2000; 407(1-2): 65-72.
34. Sabetkasai M, Khansefid N, Yahyavi SH, Zarrindast MR. Baclofen and antidepressant-induced antinociception in formalin test: possible GABA(B) mechanism involvement. Psychopharmacology (Berl) 1999; 142(4): 426-31.
35. Asahi Y, Yonehara N. Involvement of GABAergic systems in manifestation of pharmacological activity of desipramine. Jpn J Pharmacol 2001; 86(3): 316-22.
36. Sands SA, McCarson KE, Enna SJ. Relationship between the antinociceptive response to desipramine and changes in GABAB receptor function and subunit expression in the dorsal horn of the rat spinal cord. Biochem Pharmacol 2004; 67(4): 743-9.
37. Ghelardini C, Galeotti N, Bartolini A. Amitriptyline and clomipramine activate Gi-protein signaling pathway in the induction of analgesia. Naunyn Schmiedebergs Arch Pharmacol 2002; 365: 1-7.
38. Ulugol A, Karadag HC, Tamer M, Involvement of adenosine in the anti-allodynic effect of amitriptyline in streptozotocin-induced diabetic rats. Neurosci Lett 2002; 328(2): 129-32.
39. Zarrindast MR, Matinrokh H, Mojtahedzadeh-Ardebili P. Adenosine receptor agonists or antagonists alter antinociception, but did not show an interaction with imipramine-induced antinociception in the formalin test in mice. Eur Neuropsychopharmacol 2003; 13(3): 165-72.
40. Phillis JW, Wu PH. The effect of various centrally active drugs on adenosine uptake by the central nervous system. Comp Biochem Physiol 1982; 72C: 179-87.
41. Sawynok J. Adenosine receptor activation and nociception. Eur J Pharmacol 1998; 347: 1-11.
42. Sawynok J, Reid AR, Esser MJ. Peripheral antinociceptive action of amitriptyline in the rat formaline test: involvement of adenosine. Pain 1999; 80: 45-55.
43. Sawynok J, Esser MJ, Reid AR. Peripheral antinociceptive actions of desipramine and fluoxetine in an inflammatory and neuropathic pain test in the rat. Pain 1999; 82: 149-58.
44. Taylor BK. Pathophysiologic mechanisms of neuropathic pain. Curr Pain Headache rep 2001; 5: 151-61.
45. McLachlan EM, Janig W, Devor M, Michaelis M. Peripheral nerve injury triggers noradrenergic sprouting within dorsal root ganglia. Nature 1993; 363: 543-6.
46. Chabal C, Jacobson L, Russell LC, Burchiel KJ. Pain response to polineuromal injection of normal saline, epinephrine, and lidocaine in humans. Pain 1992; 49: 9-12.
47. 2A receptors potentiates pain produced by inflammatory mediators. Neuropharmacology 1996; 35: 99-110.
48. Esser MJ, Sawynok J. Acute amitriptyline in a rat model of neuropathic pain: differential sympom and route effects. Pain 1999; 80: 643-53.
49. Sawynok J, Esser MJ, Reid AR. Antidepressants as analgesics: an overview of central and peripheral mechanisms of action. J Psychiatry Neurosci 2001; 26 (1): 21-9.
50. Stein C. The control of pain in peripheral tissue by opioids. N Engl J Med 1995; 332: 1685-90.
51. Strumper D, Durieux ME. Antidepressants as long-acting local anesthetics. Reg Anesth Pain Med 2004; 29 (3): 277-85.
52. Barber MJ, Starmer CF, Grant AO. Blockade of cardiac sodium channels by amitriptyline and diphenylhydantoin. Evidence for two use-dependent binding sites. Circ Res 1991; 69: 677-696.
53. Bielefeldt K, Osaki N, Whiteis C, Gebhart GF. Amitriptyline inhibits voltage-sensitive sodium currents in rat gastric sensory neurons. Dig Dis Sci 2002; 47: 959-966.
54. Kral MG, Xiong Z, Study RE. Alteration of Na+ currents in dorsal root ganglion neurons from rats with a painful neuropathy. Pain 1999; 81: 15-24.
55. Heughan CE, Allen GV, Chase TD, Sawynok J. Peripheral amitriptyline suppresses formalin-induced Fos expression in the rat spinal cord. Anesth Analg 2002; 94(2): 427-31.
56. Pancrazio JJ, Kamatchi GL, Roscoe AK, Lynch C 3rd. Inhibition of neuronal Na+ channels by antidepresant drugs. J Parmacol Exp Ther 1998; 284: 208-14.
57. Gerner P, Mujtaba M, Sinnott CJ, Wang GK. Amitriptyline versus bupivacaine in rat sciatic nerve blockade. Anesthesiology 2001; 94: 661-7.
58. Gerner P, Haderer AE, Mujtaba M, Sudoh Y, Narang S, Abdi S, et al. Assessment of differential blockade by amitriptyline and its N-methyl derivative in different species by different routes. Anesthesiology 2003; 98(6): 1484-90.
59. Sudoh Y, Cahoon EE, Gerner P, Wang GK. Tricyclic antidepressants as long-acting local anesthetics. Pain 2003; 103(1-2): 49-55.
60. Fridrich P, Eappen S, Jaeger W, Schernhammer E, Zizza AM, Wang GK. Phase Ia and Ib study of amitriptyline for ulnar nerve block in humans. Side effects and efficacy. Anesthesiology 2004; 100: 1511-8.
61. Estebe JP, Myers RR. Amitryptiline neurotoxicity. Dose-related pathology after topical application to rat sciatic nerve. Anesthesiology 2004; 100: 1519-25.
62. Gender P. Tricyclic Antidepressants and Their Local Anesthetic Properties: From Bench to Bedside and Back Again. Reg Anesth Pain Med 2004; 29(3): 286-9.
63. Haderer A, Gerner P, Kao G, Cutaneous analgesia after transdermal application of amitriptyline versus lidocaine in rats. Anesth Analg 2003; 96(6): 1707-10.
64. Gerner P, Kao G, Srinivasa V, Narang S, Wang GK. Topical amitriptyline in healthy volunteers. Reg Anesth Pain Med 2003; 28: 289-293.
65. Kent JM. SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression. Lancet 2000; 355: 911-8.
66. Bolden-Watson C, Richelson E. Blockade by newly developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci 1993; 52: 1023-29.
67. Preskorn SH. Antidepressant drug selection: criteria and options. J Clin Psychiatry 1994; 55(Suppl A): 6-22.
68. Schreiber S, Bleich A, Pick CG. Venlafaxine and Mirtazapine. Different mechanisms of antidepressant action, common opioid-mediated antinociceptive effects - A possible opioid involment in severe depression? J Mol Neuroscience 2002; 18: 143-9.
69. Markowitz JS, Patrick KS. Venlafaxine-Tramadol similarities. Med hypotheses 1998; 51(2): 167-8.
70. Raffa RB, Friderichs E, Reimann W, Shank RP, Codd EE, Vaught JL. Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an "atypical" opioid analgesic. Journal of Pharmacology and Experimental Therapeutics 1992; 260: 275-285.
71. Moyer JA, Andree TH, Haskins JT. The preclinical pharmacological profile of Venlafaxine: a novel antidepressant agent. Clin Neuropharm 1992; 15 (supp.1 part B): 435B.
72. Michael-Titus A, Bousselmame R, Costentin J. Stimulation of dopamine D2 receptors induces an analgesia involving an opioidergic but not enkephalinergic link. Eur J Pharmacol 1990: 187: 201-7.
73. De Boer T, Maura G, Raiteri M, De Vos CJ, Wieringa J, Pinder RM. Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, mirtazapine and its enantiomers. Neuropharmacology 1988; 27: 399-408.
74. De Boer T. The effects of mirtazapine on central noradrenergic and serotoninergic neurotransmission. Int Clin Psychopharmacol 1995; 10 (Suppl 4): 19-23.
75. Millan MJ, Gobert A, Rivet JM, Adhumeau-Auclair A, Cussac D, Newman-Tancredi A, et al. Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotoninergic, transmission by blockade of alpha-2-adrenergic and serotonin 2C receptors: a comparison with citalopram. Eur J Neurosc 2000; 12: 1079-95.
76. De Boer T. The pharmacological profile of mirtazapine. J Clin Psychiatry 1996; 57 (Suppl 4): 19-25.
77. Eison AS, Eison MS, Torrente JR, Wright RN, Yocca FD. Nefazodone: preclinical pharmacology of a new antidepressant. Psychopharmacol Bull 1990; 26: 311-5.
78. Robinson DS, Roberts DL, Smith JM, Stringfellow JC, Kaplita SB, Seminaro LA, et al. The safety profile of nefaxodone. J Clin Psych 1996; 57(Suppl 2): 31-8.
79. 2 opioid and serotoninergic mechanisms. Behav Brain Res 2000; 114: 51-6.
80. Pick CG, Paul D, Eison MS, Pasternak GW. Potentiation of opioid analgesia by the antidepressant nefazodone. Eur J Pharmacol 1992; 211: 375-81.
81. Schuler P, Seibel K, Chevts V, Schaffler K. Analgesic effect of the selective noradrenaline reuptake inhibitor [reboxetine]. Nervenarzt 2002; 73(2): 149-54.
82. Bridges D, Thompson SWN, Rice ASC. Mechanisms of neuropathic pain. Br J Anaesth 2001; 87: 12-26.
83. Fishbain DA, Cutler R, Rosomoff HL, Rosomoff RS. Evidence-based data from animal and human experimental studies on pain relief with antidepressants: a structured review. Pain Med 2000; 1(4): 310-6.
84. Watson CP, Evans RJ, Reed K, Merskey H, Goldsmith L, Warsh J. Amitriptyline versus placebo in postherpetic neuralgia. Neurology 1982; 32: 671-3.
85. Max MB, Schafer SC, Culnane M, Smoller B, Dubner R, Gracely RH. Amitriptyline, but not lorazepam, relieves postherpetic neuralgia. Neurology 1988; 38: 1427-32.
86. Kishore-Kumar R, Max MB, Schafer SC, Gaughan AM, Smoller B, Gracely RH, et al. Desipramine relieves postherpetic neuralgia. Clin Pharmacol Ther 1990; 47(3): 305-12.
87. Kvinesdal B, Molin J, Froland A, Gram LF. Imipramine treatment of painful diabetic neuropathy. JAMA 1984; 251(13): 1727-30.
88. Max MB, Culnane M, Shafer SC, Gracely RH, Walther DJ, Smoller B, et al. Amitriptyline relives diabetic neuropathy pain in patients with normal or depressed mood. Neurology 1987; 37(4): 589-96.
89. Max MB, Kishore-Kumar R, Shafer SC, Meister B, Gracely RH, Smoller B. Efficacy of desipramine in painful diabetic neuropathy: a placebo-controlled trial. Pain 1991; 45(1): 3-9.
90. Sindrup SH, Ejlertsen B, Froland A, Sindrup EH, Brosen K, Gram LF. Imipramine treatment in diabetic neuropathy: relief of subjective symptoms without changes in peripheral and autonomic nerve function. Eur J Clin Pharmacol 1989; 37: 151-3.
91. Sindrup SH, Gram LF, Skjold T, Grodum E, Brosen K, Beck-Nielsen H. Clomipramine vs. desipramine vs, placebo in the treatment of diabetic neuropathy symptoms. A double-blind cross-over study. Br J Clin Pharmacol 1990; 30: 683-91.
92. Sindrup SH, Gram LF, Skjold T, Froland A, Beck-Nielsen H. Concentration-response relationship in imipramine treatment of diabetic neuropathy symptoms. Clin Pharmacol Ther 1990; 47: 509-15.
93. Sindrup SH, Tuxen C, Gram LF, Grodum E, Skjold T, Brosen K, et al. Lack of effect of mianserin on the symptoms of diabetic neuropathy. Eur J Pharmacol 1992; 43: 251-5.
94. Panerai AE, Monza G, Movilia P, Bianchi M, Francucci BM, Tiengo M. A randomized, within patient, crossover, placebo-controlled trial on efficacy and tolerability of the tricyclic antidepressants chlorimipramine and nortriptyline in central pain. Acta Neurol Scandin 1990; 82: 34-8.
95. Leijon G, Boivie J Central post-stroke pain: controlled trial of Amitriptyline and carbamazepine. Pain 1989; 36: 27-36.
96. Vrethem M, Boivie J, Amqvist H, Holmgren H, Lindstrom T, Thorell LH. A comparison of Amitriptyline and maprotiline in the treatment of painful polyneuropathy in diabetics and non-diabetics. Clin J Pain 1997; 13: 313-23.
97. Mays TA. Antidepressants in the management of cancer pain. Curr Pain Head Rep 2001; 5: 227-36.
98. Smith AJ. The analgesic effects of selective serotonin reuptake inhibitors. J Psychopharmac 1998; 12: 407-13.
99. Sindrup SH, Gram LF, Brosen K, Eshoj O, Mogensen EF. The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. Pain 1990; 42: 135-44.
100. Sindrup SH, Bjerre U, Dejgaard A, Brosen K, Aaes-Jorgensen T, Gram LF. The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy. Clin Pharmacol Ther 1992; 52: 547-52.
101. Max MB, Lynch SA, Muir J, Shoaf SE, Smoller B, Dubner R. Effects of desipramine, Amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med 1992; 326: 1250-6.
102. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ 1995; 310: 452-4.
103. McQuay H, Tramer M, Nye B, Carroll D, Wiffen PJ, Moore RA. A systematic review of antidepressants in neuropathic pain. Pain 1996; 68: 217-27.
104. Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain 1999; 83: 389-400.
105. Bohn L, Xu F, Gainetdinov RR, Caron MG. Potentiated opioid analgesia in norepinephrine transporter knock-out mice. J Neurosc 2000; 20 (24): 9040-45.
106. Yokogava F, Kiuchi Y, Ishikawa Y, Otsuka N, Masuda Y, Oguchi K, et al. An investigation of monoamine receptors involved in antinociceptive effects of antidepressants. Anesth Analg 2002; 95: 163-8.
107. Kopf A, Ruf W. Novel drugs for neuropathic pain. Curr Opin Anaesthesiol 2000; 13: 577-83.
108. Collins SL, Moore RA, McQuay HJ, Wiffen P. Antidepressants and anticonvulsants for diabetic neuropathy and postherpetic neuralgia: a quantitative systematic review. J Pain Symptom Manage 2000; 20(6): 449-58.
109. Mattia C, Coluzzi F. Antidepressants in Chronic Neuropathic Pain. Mini Rev Med Chem 2003; 3(7): 773-84.
110. Songer DA, Schulte H. Venlafaxine for the treatment of chronic pain [letter] Am J Psychiatry 1996; 153: 737.
111. Taylor K, Rowbotham MC. Venlafaxine hydrocloride and chronic pain. West J Med 1996; 165: 147-8.
112. Pernia A. Venlafaxine for the treament of neuropathic pain. J Pain Symp Manag 2000; 19: 408-10.
113. Sumpton JE, Moulin DE. Treatment of neuropathic pain with venlafaxine. Ann Pharmacother 2001; 35: 557-9.
114. Enggaard TP, Klitgaard NA, Gram LF, Arendt-Nielsen L, Sindrup SH. Specific effect of venlafaxine on single and repetitive experimental painful stimuli in humans. Clin Pharmacol Ther 2001; 69(4): 245-51.
115. Mattia C, Paoletti F, Coluzzi F. Boanelli A. New antidepressants in the treatment of neuropathic pain. A review. Minerva Anestesiol 2002; 68: 105-14.
116. Lithner F. Venlafaxine in treatment of sever painful peripheral diabetic neuropathy. Diabetes Care 2000; 23: 1710-1.
117. Tasmuth T, Hartel B, Kalso E. Venlafaxine in neuropathic pain following treatment of breast cancer. Eur J Pain 2002; 6(1): 17-24.
118. Sindrup SH, Bach FW, Madsen C, Gram LF, Jensen TS. Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial. Neurology 2003 60(8): 1284-9.
119. Brannon GE, Stone KD. The use of mirtazapine in a patient with chronic pain. J Pain Symp Manag 1999; 18 (5): 382-5.
120. Theobald DE, Kirsh KL, Holtsclaw BA, Donaghy K, Passik SD. An Open-Label, crossover trial of mirtazapine (15 and 30 mg) in cancer patients with pain and other distressing symptoms. J Pain Sympt Manag 2002; 23 (5): 442-7.
121. Jasmin L, Tien D, Janni G, Ohara PT. Is noradrenaline a significant factor in the analgesic effect of antidepressants? Pain 2003; 106: 3-8.
122. Sindrup SH, Jensen TS. In: Hansson PT, Fields HL, Hill RG, Marchettini P. Eds, Neuropathic Pain: pathophysiology and treatment. Seattle, WA IASP press 2001; 169-83.
123. Reisner L. Antidepressants for chronic neuropathic pain. Curr Pain and Headache Rep 2003; 7: 24-33.
124. DeHaven-Hudkins DL, Dolle RE. Peripherally restricted opioid agonists as novel analgesic agents. Curr Pharm Design 2004; 10(7): 743-57.
125. McCleane G. Cholecystokinin antagonists a new way to improve the analgesia from old analgesics? Curr Pharm Design 2004; 10(3): 303-14.
126. Pacher P, Kecskemeti V. Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns? Curr Pharm Design 2004; 10(20): 2463-75.